Teriflunomide Patent Expiration
Teriflunomide is Used for treating patients with relapsing forms of multiple sclerosis. It was first introduced by Sanofi Aventis Us Llc
Teriflunomide Patents
Given below is the list of patents protecting Teriflunomide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Aubagio |
US9186346 (Pediatric) | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients | Aug 04, 2034 | Sanofi Aventis Us |
| Aubagio | US9186346 | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients | Feb 04, 2034 | Sanofi Aventis Us |
| Aubagio |
US8802735 (Pediatric) | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability | Mar 14, 2031 | Sanofi Aventis Us |
| Aubagio | US8802735 | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability | Sep 14, 2030 | Sanofi Aventis Us |
| Aubagio |
US6794410 (Pediatric) | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis | Mar 12, 2027 | Sanofi Aventis Us |
| Aubagio | US6794410 | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Sep 12, 2026
(Expired) | Sanofi Aventis Us |
| Aubagio | US5679709 | Medicaments to combat autoimmune diseases |
Oct 21, 2014
(Expired) | Sanofi Aventis Us |
| Aubagio | US5459163 | Medicament to combat autoimmune diseases |
Oct 17, 2012
(Expired) | Sanofi Aventis Us |
Teriflunomide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Teriflunomide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. | Sanofi | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | Sanofi | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis | National Institute of Neurological Disorders and Stroke (NINDS) | NA |
RECRUITING
(Jun 17, 2026)
| PHASE1, PHASE2 |